Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947915 | 1.00 | MTNR1A (0.39) | MTNR1AMTNR1BMEN1KMT2ACYP3A4 | |
| SCHEMBL948935 | 0.87 | ALOX15 (0.43) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL949434 | 0.83 | KMO (0.44) | CYP2C9CYP2C19MMP2 | |
| SCHEMBL949305 | 0.83 | KMO (0.44) | CYP2C9CYP2C19MMP2 | |
| SCHEMBL27670173 | 0.83 | KMO (0.44) | CYP2C9CYP2C19MMP2 | |
| SCHEMBL7014510 | 0.81 | ALOX15 (0.42) | CYP3A4CYP2C9CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL950415 | 0.78 | ALDH1A1 (0.51) | CYP2C9CYP2C19LMNAHPGDSMN1; SMN2 | |
| SCHEMBL947775 | 0.78 | ALDH1A1 (0.51) | CYP2C9CYP2C19LMNAHPGDSMN1; SMN2 | |
| SCHEMBL28023324 | 0.77 | HPGD (0.45) | KMT2ACYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL7016500 | 0.75 | MAPT (0.52) | KMT2ACYP3A4CYP2C19LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | MTNR1A 488/4885MTNR1B 539/4885MEN1 1291/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | MTNR1A 678/4885MTNR1B 733/4885MEN1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.